Biochemical changes in Kaposi's sarcoma and experimental therapy of murine AIDS (Meeting abstract). NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Biochemical changes in Kaposi's sarcoma and experimental therapy of murine AIDS (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 34:A1120 1993. Unique Identifier : AIDSLINE ICDB/93692095
Ambrus JL; Stadler S; Nakeeb S; Toumbis C; Butsch J; Spatola G; Mathur N; Munschauer R; Chadha K; Dept. of Medicine, Buffalo General Hosp., Buffalo, NY 14203

Abstract: In patients with Kaposi's sarcoma (KS) and AIDS, there was decreased interferon-alpha (IFN-alpha) synthesizing capacity, and in KS tissue increased amounts of prostaglandin E2 (PgE2) were found. PgE2 inhibited IFN-alpha synthesis, a cAMP-dependent process. cAMP-increasing agents (eg, pentoxifylline [PX]) and PgE2 inhibitors (eg, indomethacin meclofenamate [MC]) increased IFN-alpha synthesis. In C57BL/6 mice infected with LP-BM6 retroviruses, an AIDS-like condition developed. There was hepatosplenomegaly, lymphadenopathy, leukopenia, thrombocytopenia, reduced L3T4 and LYT-2 cells and reduced IFN-alpha production. MC and PX reversed these effects.
Keywords: Acquired Immunodeficiency Syndrome/DRUG THERAPY/*PATHOLOGY Animal Dinoprostone/*BIOSYNTHESIS Human Indomethacin/*PHARMACOLOGY Interferon-alpha/*BIOSYNTHESIS Meclofenamic Acid/*PHARMACOLOGY Mice Mice, Inbred C57BL Murine Acquired Immunodeficiency Syndrome/DRUG THERAPY/*PATHOLOGY Pentoxifylline/*PHARMACOLOGY Sarcoma, Kaposi's/DRUG THERAPY/*PATHOLOGY ABSTRACTKWDacquiredimmunodeficiencysyndrome/drugtherapy/KWDpathologyanimaldinoprostone/KWDbiosynthesishumanindomethacin/KWDpharmacologyinterferon-alpha/KWDbiosynthesismeclofenamicacid/KWDpharmacologymicemice,inbredc57blmurineacquiredimmunodeficiencysyndrome/drugtherapy/KWDpathologypentoxifylline/KWDpharmacologysarcoma,kaposi's/drugtherapy/KWDpathologyabstract
930730
M9370999

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .